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DEVELOPMENT AND CHARACTERIZATION OF A RECOMBINANT ORF VIRUS 




Orf virus (ORFV), the type member of the genus Parapoxvirus of the family 
Poxviridae, causes orf or cutaneous pustular dermatitis in sheep and goats. ORFV is a 
ubiquitous virus capable of re-infecting its hosts multiple times over time. ORFV causes a 
non-systemic, self-limiting disease which is usually restricted to the skin surrounding the 
virus entry sites. ORFV has evolved several immunomodulatory proteins (IMPs) that evade 
and/or modulate host immune responses to infection and contribute to virus virulence and 
disease pathogenesis. Given biological properties and unique immunomodula tory 
properties, ORFV has gained significant attention in recent years for its potential as a 
vaccine delivery vector for use in veterinary medicine. Here we explored the potential of 
ORFV as a vaccine delivery vector for use in swine. The spike (S) protein of porcine 
epidemic diarrhea virus (PEDV) was used as our model antigen and the immunogenic ity 
and protective efficacy of a recombinant ORFV expressing the full length S protein of 
PEDV (ORFV-PEDV-S) was assessed in pigs. The ORFV-PEDV-S virus was generated 
by homologous recombination and the DNA sequences of PEDV S were inserted into the 
ORFV121 gene locus, an immunomodulatory protein (IMP) encoded by ORFV that 
contributes to the virus virulence. The resultant recombinant virus was characterized in 
vitro and its immunogenicity and protective efficacy evaluated in vivo. Results of our study 
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show that intramuscular (IM) immunization of swine with the ORF-PEDV-S recombinant 
virus elicited robust humoral immune responses and protected animals from clinica l 
disease. Additionally, IM immunization with the ORFV-PEDV-S led to reduced virus 
shedding in feces. The results of this study provide important information on the feasibility 




Chapter 1: Literature Review 
Orf virus (ORFV) 
Orf virus (ORFV) is the type member of the genus Parapoxvirus of the family 
Poxviridae 1. The ORFV genome consists of double-stranded DNA (dsDNA) molecule of 
approximately 138 kbp in length 2. The ORFV genome is organized in a central core that 
is flanked by two terminal variable genomic regions 2. The core genomic region contains 
genes that are conserved across different poxviruses and encodes proteins involved in basic 
mechanisms of virus replication transcription and morphogenesis 3. Whereas the genomic 
ends contain variable genes encoding for immunomodulatory proteins (IMPs) with putative 
functions on virus virulence, pathogenesis and host range 2. 
ORFV is an epitheliotropic virus and keratinocytes and epithelial cells in the oral 
mucosa are the major – if not the only – cell types to support ORFV replication in the host  
4,5. ORFV replicates in the cytoplasm of infected cells, thus the virus packages its own 
transcription/replication machinery in the virions 6.  
Poxviruses present a distinct transcription strategy that can be broadly divided in 
three categories (early, intermediate, and late) based on the time that each gene category is 
transcribed 7. Early genes are expressed within minutes to the first hours of infection (20 
min to 3-4 h), and encode immunomodulatory proteins (IMPs) that play roles in host-
immune evasion and virus virulence 2 or yet factors that will facilitate the expression of 
intermediate genes 8,9. Intermediate genes are usually transcribed between 3-5 hours post 
infection and encode for transcription factors that regulate transcription of late poxviral 
2 
genes 9,10. The products of intermediate and late genes participate in the replication of the 
virus genomic DNA, and are directly involved in virion assembly and morphogenesis 7.    
ORFV infection   
 ORFV is the causative agent of orf or contagious pustular dermatitis, an acute skin 
condition affecting sheep and goats 11,12,13. Orf typically presents as scabby lesions 
affecting the skin around the mouth, lips, nostrils, nares, udder, and teats 14. ORFV enters 
through damaged skin and replicates in proliferating keratinocytes in the skin or their 
counterparts in the oral mucosa surrounding the virus entry sites 15. Following an 
incubation period that varies between 3-4 days, the disease starts with erythema and 
progresses through the stages of papules, pustules, vesicles and scabs 4. Orf lesions usually 
resolve within 4-6 weeks and scabs fall off leaving an area of keratinized epithelium 
covering the site of virus replication 16. Infections with ORFV are localized to the site of 
infection and there is no evidence of systemic dissemination of the virus 4. ORFV is a 
ubiquitous virus and the disease occurs worldwide in areas where sheep and goats are 
raised. Mortality associated with ORFV infection is usually low; however, morbidity may 
reach up to 90% in young animals 13.  
 One of the unique properties of ORFV is its ability to re-infect animals mult ip le 
times; however, in re-infections the disease is usually milder and resolve sooner (within 2-
3 weeks) than in primary infections 17. Presumably, this is due to immunomodula tory 
properties of the virus, including, for example, the lack of neutralizing antibodies against 
ORFV in infected animals 18.  
3 
Immune responses to ORFV  
 The immune responses to ORFV are short-lived and animals can be repeatedly re-
infected throughout their life 5,18,19. Immune responses to ORFV are initiated by 
keratinocytes upon infection 20. Keratinocytes are the most abundant cell type in the 
epidermis and function as sentinels of the skin. These cells express several pattern 
recognition receptors (PRRs) at the cell surface or intracellularly that sense invading 
pathogens and trigger the initial steps of the immune responses 21. The PRRs recognize 
signatures in invading pathogens named pathogen associated molecular patterns (PAMPs). 
PAMPs recognize molecules that are unique to pathogens and not present on normal 
eukaryotic cells 22. One specific PRR, called toll-like receptor 3 (TLR-3) recognizes 
double-stranded RNA (dsRNA), a common product of viral infections 23. Recognition of 
PAMPs by the PRRs of keratinocytes and resident immune cells leads to the secretion of 
pro-inflammatory and immune-stimulating cytokines 20. Cytokines released in response to 
ORFV replication include interferon- α (IFN- α), IFN-γ, interleukin beta-1beta (IL-beta1), 
IL-8, and granulocyte/monocyte-colony stimulating factor (GM-CSF) 3,24–27.  
Following ORFV infection, the immune response is characterized by the 
recruitment of CD4+ T helper cells, Natural Killer (NK) cells, and dendritic cells to the 
site of infection 28,29. It is common to observe an influx of neutrophils, CD8+ cytotoxic T 
cells, and B cells that accumulate in areas adjacent to or beneath infected cells 19. It has 
also been observed that there is an abundance of γδ T cells during primary infection 3.  
 CD4+ T cells are the predominant cell type in both primary and secondary 
infections and are the most important cells in determining the outcome of infection. CD8+ 
T cells and B cells have also been observed in both primary and secondary infections, 
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though the role of these cells on virus clearance remains unknown 28,30. Experimenta l 
treatment with cyclosporine A, an immunosuppressive drug that inhibits T-cell 
development, during an ORFV infection resulted in a significant increase in the severity of 
the disease that could be attributed to a notable decrease in the production of IL-2 and IFN-
γ 31. A similar experiment using neutralizing antibodies against CD4+, CD8+, and γδ T-
cells revealed that the number of CD4+ T cells was inversely proportional to the severity 
of the disease. A similar, yet much less dramatic effect was observed with depleted 
populations of CD8+ or γδ T-cells 30.  
 As previously noted, ORFV can re-infect the same animal multiple times. 
Secondary infections typically present with a less severe form of the disease and resolve 
sooner than primary infections 32. Notably, during secondary infections by ORFV a 
significantly higher number of IFN-γ producing cells are observed. There is also an 
observed upregulation of TNF-α expression, one of the primary inducers of the nuclear-
factor kappaB (NF-κB) pathway. It has been suggested that IFN-γ plays an important role 
in the early events leading to clearance of ORFV upon secondary exposure 33.  
A hallmark of ORFV infection is the absence of neutralizing antibodies in naturally 
infected animals 34. Seroconversion against immunodominant antigens has been observed 
in sheep; however these antibodies don’t seem to play a role in protection 4. These findings 
explain why the transfer of antibody from infected mother via the colostrum does not 
protect lambs from infection 35. Presumably, the lack of neutralizing antibodies against 
ORFV is one of the primary reasons for the virus to repeatedly re-infect its host. 
Additionally, immunomodulatory proteins (IMPs) encoded by ORFV are thought to play 
a role on immune evasion 36. 
5 
Immunomodulation by ORFV 
Like other poxviruses, ORFV has evolved several mechanisms to evade and 
modulate host immune responses to infection 6. ORFV encodes various genes with putative 
immunomodulatory and virulence functions that likely inhibit host responses to infect ion. 
Several of these IMPs will be discussed below.  
One of the best characterized virulence factors is the ORFV orthologue of the 
mammalian vascular endothelial growth factor (VEGF) 37. The ORFV VEGF (ORFV132) 
is a bone fide virulence factor because it does not inherently evade or avoid host immune 
responses but contributes to ORFV virulence in sheep. The ORFV VEGF functions in a 
similar fashion as its mammalian counterpart, stimulating epidermal keratinocyte 
proliferation, and thus presumably providing more target cells for virus infection and 
replication 38. Notably, deletion of the VEGF gene from the ORFV genome has shown to 
markedly attenuate the virus and decrease disease severity in sheep 39. It has been suggested 
that VEGF encoded by ORFV enhances virus replication by both increasing the number of 
susceptible cells and also inhibiting apoptosis in infected cells 3,18,39. 
 ORFV has also evolved various genes that target host immune responses to 
infection. One of the first identified ORFV IMPs is the interferon (IFN) resistance factor 
(OVIFNR) 40. OVIFNR is an a homolog of the well-characterized vaccinia virus E3L gene 
36 and it functions by preventing detection of viral double-stranded RNA (dsRNA) in 
infected cells. OVIFNR exerts its function by binding dsRNA, subsequently inhibiting the 
activation of cellular protein kinase R (PKR) or the 2’-5’-oligoadenylate synthetase 
enzyme (OAS1).  The PKR works by phosphorylating itself and then the α subunit of 
translation elongation initiation factor eIF2, successfully halting the production of both 
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cellular and viral proteins 41, whereas the OAS1 functions by activating RNAse L that 
degrades viral and cellular RNA, successfully inhibiting translational activity 42. Both 
mechanisms lead to an antiviral state following type-I IFN signaling 36.  
 Another ORFV gene that inhibits host immune responses is the granulocyte 
monocyte colony stimulating factor (GM-CSF) and interleukin 2 (IL-2) inhibitor (GIF; 
ORFV117). Although the precise function and activity of the GIF is not completely 
understood, the protein has been shown to bind to GM-CSF and IL-2 (pro-inflammatory 
cytokine), presumably inhibiting their action  43. GM-CSF plays an important role in the 
recruitment and production of white blood cells, mainly granulocytes and monocytes 44. 
These cells consist mostly of neutrophils, macrophages, and dendritic cells that play 
important roles orchestrating immune responses 45. IL-2 is a pro-inflammatory cytokine 
that functions in the development and activation of T cells and NK cells 46. Thus, IL-2 is 
directly involved in the production of IFN-γ, which has been shown to be detrimental to 
ORFV infection 31. Notably, the GIF is secreted from ORFV infected cells and local 
inhibition of GM-CSF and IL-2 may be advantageous for ORFV replication in 
keratinocytes.  
 ORFV also encodes a homologue of mammalian IL-10 47–49. IL-10 is an 
immunoregulatory and anti-inflammatory cytokine often functioning by downregula t ing 
inflammatory responses, inhibiting proliferation of immune cells and promoting healing 50. 
The ORFV IL-10 (vIL-10) functions in a similar fashion to its ovine counterpart, with the 
secreted product inhibiting TNF-α and IL-8 production by macrophages and keratinocytes 
51. In addition vIL-10 has been shown to inhibit the production of IFN-γ 49.  
7 
NF-κB and ORFV 
 The NF-κB pathway is an important early innate immune mediator involved in 
orchestrating inflammation and immune responses upon pathogen recognition 52. Early 
signaling by NF-κB and consequence gene transcription play important roles in different 
areas of innate and adaptive immunity. Given the central role played by NF-κB on 
modulation of innate and inflammatory responses to infection, it is not surprising that 
several viruses have evolved mechanisms that specifically interfere with NF-κB activation 
53. Notably, ORFV has been shown to encode at least three proteins that target the NF-κB 
signaling pathway 54–56. 
The NF-κB family of transcription factors comprises five proteins (RelA or p65, 
RelB, c-Rel, p50 and p52) that form homo- or heterodimers and regulate transcription of 
several genes involved in innate immune responses, cell cycle and apoptosis 57. During 
homeostasis NF-κB members remain in the cell cytoplasm bound to nuclear factor of kappa 
light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) 52. IκBα serves as an 
inhibitory protein that mask the nuclear localization signals of the NF-κB p65-p50 
complex, sequestering it to the cytoplasm and preventing its transcriptional activity 57.  
 Activation of the NF-κB pathway can result from a vast array of stimuli includ ing 
cytokines, and bacterial or viral products 58. These stimuli are typically triggered in 
response to infection, inflammation, or cellular stress 59. These signals are recognized by 
cellular PRRs, resulting in pathway activation. Once activated, NF-κB regulates expression 
of several genes that function during inflammation, apoptosis, and innate and adaptive 
immune responses 52. Given the role of NF-κB in such critical cellular processes, it is not 
surprising that many viruses have evolved strategies to modulate activation of this pathway. 
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ORFV for example encodes at least three genes ORFV002, ORFV024, and ORFV121 that 
have been recently shown to inhibit activation of the NF-κB signaling pathway.  
These proteins target both nuclear and/or cytoplasmic events leading to NF-κB 
mediated gene transcription 54–56. The protein encoded by ORFV002 functions by targeting 
nuclear events that regulate NF-κB transcriptional activity, suppressing the acetylation of 
nuclear NF-κB p65 by p300 56. ORFV002 was found to directly interact with nuclear NF-
κB p65, interfering with the formation of the p300-p65 complex necessary for NF-κB p65 
acetylation. ORFV024 functions in the cytoplasm by inhibiting phosphorylation of IKK 
alpha and beta 54, whereas ORFV121 binds to NF-κB p65 in the cell cytoplasm inhibit ing 
its phosphorylation and translocation to the nucleus 55. Notably, deletion of ORFV121 from 
the ORFV genome resulted in a markedly attenuated disease phenotype in sheep 55. These 
immonomodulatory properties of ORFV make the virus a promising candidate for vaccine 
delivery in animal species, with genes encoding IMPs  representing promising sites for 
insertion foreign DNA in ORFV-based vectors.  
Use of ORFV as a vaccine delivery vector 
 Large DNA viruses have long been used as vaccine vectors for delivery of 
heterologous antigens in human and veterinary medicine 60. There are several properties 
that make viruses attractive candidates as vaccine delivery platforms. Viruses are capable 
of delivering and expressing heterologous viral proteins directly in target host cells 61–63. 
Live virus-vectors are also promising in that they can induce humoral and cellular immune 
response, thus resembling the immunity following a natural virus infection 62,64. The 
restricted host-range of many large DNA viruses, especially poxviruses, makes them useful 
in delivering target antigens in non-permissive species 15. Another advantage of using 
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poxviral-vectors is that they replicate in the cytoplasm 65, which eliminates the possibility 
that the viral DNA will be incorporated in the host genome 66. Several large DNA virus-
vectored vaccines are currently available, including those that utilize poxviruses. One of 
the most recognizable of these would be the well-characterized vaccinia virus 67–69.  
 One of the major problems with viral vectors is the interference of pre-existing 
immunity against the vector which often precludes the development of immune responses 
against the heterologous antigens 70. In these cases, the vector can only be used once, with 
a different vector delivering the same antigen being necessary for any type of boost 
vaccination or delivery of another antigen.  
 Notably, ORFV-based vectors present several unique properties that may favor 
their use over current veterinary viral vectors. ORFV has a restricted host range and causes 
only localized, self-limiting infections 15. ORFV is also capable of inducing robust immune 
responses in permissive and non-permissive hosts 71. Additionally, since ORFV does not 
induce neutralizing antibody responses, it has the potential to be used multiple times either 
to boost a previous vaccination or to deliver new antigens against different diseases. The 
IMPs encoded by ORFV also represent potential sites where foreign DNA could be inserted 
into the ORFV genome 54–56. These genes are non-essential for ORFV replication and some 
genes contribute to ORFV virulence in the natural host, which allows the development of 
an attenuated viral vector for vaccine delivery in animal species.  
 The use of ORFV as a vaccine delivery platform has been explored. Most of these 
vaccines use the highly attenuated ORFV strain D1701-V, which was passaged in Vero 
cell cultures for over 200 passages resulting in multiple gene deletions and rearrangements 
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throughout the genome. Studies using the ORFV D1701-V describe the insertion of 
heterologous viral antigens into the VEGF locus 72. These studies have shown that ORFV 
is capable of eliciting immune responses against viruses like influenza A, rabbit 
hemorrhagic disease virus (RHDV), and rabies virus 73–75. Notably, ORFV D1701 
recombinant expressing the pseudorabies virus (PRV) glycoproteins gC and gD or the 
classical swine fever virus E2 glycoprotein protected swine from PRV and CSFV 
challenge, respectively 76,77. In this study we evaluated the potential of ORFV vectoring 
the full length spike (S) protein of porcine epidemic diarrhea virus.  
Porcine Epidemic Diarrhea Virus (PEDV)  
 Porcine epidemic diarrhea virus (PEDV) is an enteric pathogen that causes acute 
and significant disease in swine 78. Infection with PEDV often presents as acute watery 
diarrhea, vomiting, dehydration, lethargy, and anorexia 79. The virus is capable of infect ing 
swine of all ages, but causes the most severe disease in piglets less than 7 days of age 
resulting in mortality rates as high as 100% in suckling piglets 80. Death associated with 
PEDV is often occurs due to dehydration resulting from severe watery diarrhea, the 
hallmark symptom for which PEDV was named 81–83 . PEDV spreads via the fecal-oral 
route and is extremely infectious and transmissible, often quickly spreading from one farm 
to another 84,85. It has also been suggested that PEDV can remain infectious and be 
transported via the aerosolized route 86. Since its initial discovery in the 1970’s in Europe, 
PEDV remained endemic in Asia, causing significant economic losses to the swine industry 
80. In recent years, the first cases of PEDV were reported in the United States. Within its 
first year of emergence in the U.S., PEDV was responsible for the death of approximate ly 
7 million piglets (~10% of the domestic pig population) 87.  
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Virus structure and properties 
 PEDV is a member of the genera Αlphacoronavirus in the family Coronaviridae. It 
has a genome approximately 28 kb in size consisting of four structural proteins: Spike (S), 
membrane (M), envelope (E), and nucleocapsid (N) 88. PEDV also encodes for 16 
additional non-structural proteins, many of which have been suggested to serve important 
functions in evading host anti-viral responses 89. Of the structural proteins, the S protein is 
a type I glycoprotein of 1,383 amino acids in length with a predicted molecular weight 
ranging from 180-220 kDa 80. The PEDV S has been characterized as playing several 
critical rolls in virus attachment and entry into cells, in addition to being the primary target 
for anti-PEDV neutralizing antibodies 90. Therefore the PEDV S protein has been targeted 
for the development of recombinant PEDV vaccines 90. 
Pathogenesis 
 Following infection, PEDV replicates in intestinal enterocytes 91. These cells 
express abundant amounts of the porcine aminopeptidase N receptor which served as a 
receptor for PEDV 92. Binding is facilitated by the PEDV S protein, which then cleaves 
into subunits S1 and S2, causing a conformational change in the receptor and 
internalization of the virus by the cell 93. Replication of PEDV in enterocytes leads to cell 
lysis, causing villous atrophy and subsequent destruction of the brush border 94. Due to the 
importance of these cells in digestion and nutrient absorption, their destruction by PEDV 
often leads to malabsorption and severe, acute watery diarrhea 91. Replicating virus is then 
shed in the feces where it is spread to other animals 95.  
 Despite its ability to cause disease in swine of all ages, PEDV has notably high 
mortality rates in suckling piglets. It remains unclear as to why PEDV causes higher 
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mortality rates in suckling pigs when compared to older pigs 83. Physiological factors 
associated with the age of the pigs may play important roles, specifically the slower rate of 
enterocyte regeneration in young pigs 96. Although mortality is rare in older animals, there 
is still considerate morbidity associated with PEDV infection.  
Prevention and Vaccines 
 Vaccination remains the most efficient and cost-effective method of preventing or 
controlling viral diseases 97. Development of vaccines for enteric pathogens like PEDV, 
however, remains a major challenge, especially because of the need for lactogenic 
immunity 98,99. One of the earliest and most crude strategies to preventing further PEDV 
infection was exposure of pregnant sows to live, infectious virus 87. Older animals typically 
are not susceptible to PEDV associated mortality and will recover from the disease 82. Sows 
with previous exposure to PEDV are able to transfer PEDV sIgA antibodies passively to 
their offspring in the colostrum, effectively protecting them from disease 98. Both IgG and 
IgA are secreted in colostrum, with 60% actually being IgG, yet only the J chain-containing 
IgA is stable and resists degradation in the gut 100.  Exposure and subsequent immunity to 
PEDV can be achieved by exposing animals to feces or minced intestines of infected 
animals 101. This strategy is extremely crude and has several negative implications, 
especially the idea of using virulent virus on healthy animals, as well as the potential for 
its spread to other animals and farms and the potential to expose animals to other virulent 
and damaging diseases 102. To date, one of the best strategies for preventing PEDV disease 
comes in the form of taking proper sanitary and hygiene precautions to prevent spread of 
the highly infectious virus.  
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 Most current PEDV vaccines have been developed for strains circulating in Asia 80. 
Since PEDV emergence in Asia, variants of the first PEDV strain CV777 obtained in 1977 
in Europe in either inactivated or attenuated forms. Many of these vaccines were developed 
by passing the virus multiple times in cell culture, leading to significant mutation 
accumulation and a genome that can often be significantly different from the original 103. 
Two commonly used viruses are the Korean KPEDV-1 strain, that was attenuated by 
passaging the virus 93 times in Vero cells 104, and the Japanese P-5V strain 105. Both strains 
are considered to be moderately efficient producers of lactogenic immunity, meaning they 
are capable of passive immunization of suckling piglets 105.  
 Other strategies exist that target the manner in which mucosal immunity is 
generated, specifically by delivering the vaccine by oral routes. A Korean vaccine using a 
highly passaged attenuated DR13 strain of PEDV saw dose dependent levels of lactogenic 
immunity and passive protection when animals were inoculated via the oral route 106. The 
vaccine protected 25% of the pigs when given at low doses and up to 50% when given at 
doses that were 20 times higher. Despite this moderate efficacy, the vaccine failed to inhib it 
or decrease levels of virus shedding, an important aspect to consider when developing 
vaccines.  
 Another oral-vaccination strategy exists incorporating the use of transgenic plants 
to produce immunogenic PEDV proteins 98. In one study, transgenic tobacco plants 
expressing the PEDV S protein were able to induce neutralizing antibodies in mice when 
the plant was administered orally. This mechanism could prove extremely promising as it 
could be both cost effective and mimics the natural mechanism of PEDV exposure, 
triggering mucosal immunity at sites most likely to encounter live PEDV upon challenge.  
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In recent years, pork producers have been seeing a decrease in the already 
questionable efficacy of PEDV vaccines. Some suggest that this is the result of the recent 
emergence of genetically different, more virulent strains of PEDV 107, while other contest 
that the recent spotlight on PEDV has simply exposed their already mediocre efficacy. One 
inherent problem is based on the methods by which these vaccines are developed, which 
currently are either by inactivation or attenuation. These two methods are preferential, as 
they are easy and cost effective to produce 108. Inactivated vaccines often lack in efficacy 
due to their lack of replication and stimulation of robust local mucosal immunity 109. 
Whereas the attenuation process may lead to a vaccine that is too attenuated, thus elicit ing 
inefficient immune responses. Another concern of live-attenuated strains of PEDV is their 
potential to possibly revert to a highly virulent phenotype. Studies conducted on recently 
emerging infectious strains of PEDV have suggested their derivation from an attenuated 
vaccine; the mutations having caused them to actually become more virulent 107.  
For these reasons, it is paramount that new PEDV vaccines are developed which 
utilize new and emerging antigen delivery mechanism, with specific focus on the induc tion 
of mucosal immunity and targeting of immunodominant, protective epitopes. There are 
several ways in which lactogenic immunity can be targeted and continued research is being 
made to improve these methods 110. As far as immunodominant proteins go, the PEDV S 
protein has been well characterized as the primary target for neutralizing antibodies 111. 
Further research has gone to show several important B-cell epitopes on the PEDV S 112. 
Therefore, the PEDV S is one of the most promising candidates in terms of developing new 
recombinant PEDV vaccines. As previously stated, researchers have already 
15 
experimentally expressed PEDV-S in transgenic tobacco plants which successfully 
protected mice from PEDV infection 98. 
Other vaccination strategies, including the expression of recombinant PEDV S or 
its delivery by live-virus-vectors, may hold the key for designing functional and efficac ious 
PEDV vaccines. One of the first U.S. licensed vaccines, developed by Harris Vaccine Inc., 
utilized an alphavirus vector to vaccinate against PEDV 113. There has also been the 
development of inactivated vaccines using strains isolated from infected pigs in the United 
States 114,115. Regardless of the mechanism of delivery, the severity of disease caused by 
PEDV make the development of a successful vaccine critical for preventing disease in 
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 The parapoxvirus Orf virus (ORFV) has long been recognized for its 
immunomodulatory properties in permissive and non-permissive animal species. Here, a 
new recombinant ORFV expressing the full-length spike (S) protein of porcine epidemic 
diarrhea virus (PEDV) was generated and its immunogenicity and protective efficacy were 
evaluated in pigs. The PEDV S was inserted into the ORFV121 gene locus, a novel 
immunomodulatory gene that inhibits activation of the nuclear factor-κ B (NF-κB) 
signaling pathway and contributes to ORFV virulence in the natural host. The recombinant 
ORFV-PEDV-S virus efficiently and stably expressed the PEDV S protein in cell culture 
in vitro. Intramuscular (IM) prime-boost immunizations with the recombinant ORFV-
PEDV-S in 3-week-old pigs elicited robust serum IgG, IgA and neutralizing antibody 
responses against PEDV. Additionally, IM immunization with the recombinant ORFV-
PEDV-S virus protected pigs from clinical signs of porcine epidemic diarrhea (PED) and 
reduced virus shedding in feces upon challenge infection. These results demonstrate the 
suitability of ORFV121 gene locus as an insertion site for heterologous gene expression 
and delivery by ORFV-based viral vectors. Additionally, the results provide evidence of 
the potential of ORFV as a vaccine delivery vector for enteric viral diseases of swine. This 
study may have important implications for future development of ORFV-based viral 






Orf virus (ORFV) is the type member of the genus Parapoxvirus of the family 
Poxviridae 6. ORFV is a highly epitheliotropic virus, and keratinocytes and epithelial cells 
in the oral mucosa are the most important - if not the only - cell type to support ORFV 
replication in natural hosts 5. The ORFV genome consists of a double-stranded DNA 
molecule of approximately 138 kbp in length and contains 131 putative genes 2. ORFV has 
been long known for its immunomodulatory properties 71,116. Many genes with 
immunomodulatory functions have been identified in the ORFV genome, including a 
homologue of interleukin 10 (IL-10) 47, a chemokine binding protein (CBP) 117, a secreted 
inhibitor of granulocyte-monocyte colony-stimulating factor (GM-CSF) and IL-2 43, a 
vascular endothelial growth factor (VEGF) 38, an interferon (IFN)-resistance gene 118, and, 
more recently, three inhibitors of the nuclear factor-κ B (NF-κB) signaling pathway 
(ORFV002, ORFV024 and ORFV121) 54–56. Among these, the IL-10 homologue, the VEGF 
gene and the NF-κB inhibitor ORFV121 have been shown to contribute to ORFV virulence 
in the natural host 49,55,119. 
ORFV has been historically used as a preventive or therapeutic agent in veterinary 
medicine 116. The potential of ORFV as a recombinant vaccine delivery vector has been 
explored, and recombinant ORFV vectors based on the highly attenuated ORFV strain 
D1701 have been shown to induce protective immunity against several viral diseases in 
permissive and non-permissive animal species 72–77,120–122. Notably, ORFV D1701-based 
recombinants expressing the Pseudorabies virus (PRV) glycoproteins gC or gD induced 
protective immunity against PRV infection in pigs 76, while a recombinant ORFV 
expressing the classical swine fever virus (CSFV) E2 glycoprotein protected swine against 
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intranasal challenge with a virulent CSFV strain 77. These studies demonstrate the efficacy 
of ORFV-based vectors in eliciting protective immune responses in swine. In the present 
study, the potential of ORFV as a vaccine delivery vector for enteric viral diseases of swine 
was investigated. The porcine epidemic diarrhea virus (PEDV) spike (S) glycoprotein was 
used as a model antigen to evaluate the immunogenicity and protective efficacy ORFV-
based vectors in pigs.  
Porcine epidemic diarrhea virus (PEDV), a member of the genus Αcoronavirus of 
the family Coronaviridae, causes severe enteric disease (porcine epidemic diarrhea; PED) 
in pigs 123,124. PEDV infects pigs of all ages, producing high mortality rates (50-100%) in 
suckling piglets and weight loss due to diarrhea in older animals 123. The virus replicates 
primarily in enterocytes of the small intestines leading to villous atrophy and malabsorptive 
diarrhea followed by electrolyte imbalance, metabolic acidosis and death 83. Characteristic 
clinical signs of PED include watery diarrhea, vomiting, anorexia, dehydration and death 
125. In older pigs, the disease is usually milder resulting in low mortality rates 125.  
The PEDV genome is a large (~28 Kb) positive sense RNA molecule that contains 
six open reading frames (ORFs), encoding the replicase proteins (pp1a and pp1ab), four 
structural proteins (Spike [S], envelope [E], membrane [M], and nucleoprotein [N]) and 
one accessory protein (ORF3) 80,125. Among the structural proteins, the S protein is the 
major envelope glycoprotein responsible for virus attachment and entry 112,126,127. Given its 
critical function in attachment and entry, the S glycoprotein is the main target for 
neutralizing antibodies (NA) against PEDV 127–130, with several neutralizing epitopes being 
mapped to this glycoprotein 112,126–128,131.  
20 
Here a novel recombinant ORFV expressing the full- length PEDV S protein 
(ORFV-PEDV-S) was generated, and its immunogenicity and protective efficacy were 
evaluated in pigs. The PEDV S coding sequences were inserted into the ORFV121 gene 
locus, a recently characterized immunomodulatory gene of ORFV that contributes to the 
virus virulence in the natural host 55. Results from immunization studies in pigs show that 
intramuscular (IM) immunization with the ORFV-PEDV-S elicited S-specific IgG, IgA 
and neutralizing antibody responses. Notably, animals immunized with the ORFV-PEDV-
S via the IM route were protected from clinical signs of PED, and presented reduced virus 
shedding in feces after oral challenge with a virulent PEDV strain.     
Materials and methods 
Cells and viruses.  Primary ovine fetal turbinate- (OFTu), porcine kidney- (PK-15; ATCC 
PTA-8244) and Vero-76 cells (ATCC® CRL-1587™)  were cultured at 37oC with 5% CO2 
in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 
2 mM L-glutamine, and containing penicillin (100 U/mL), streptomycin (100 µg/mL) and 
gentamicin (50 µg/mL).  
ORFV strain IA82 2 was used as the parental virus to construct the recombinant Orf 
virus expressing the PEDV S protein (ORFV-PEDV-S) and in all experiments involving 
the use of wild type ORFV. Wild type and recombinant ORFV viruses were amplified in 
primary OFTu cells. PEDV strain USA/CO/2013 (CO13) was obtained from the National 
Veterinary Services Laboratory (NVSL) and propagated in Vero-76 cells in the presence 
of 1.5 µg/mL TPCK treated trypsin (Sigma Aldrich, St. Louis, MO). 
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Construction of ORFV-PEDV-S recombination plasmid. The full-length coding sequence 
of the spike gene of PEDV strain CO13 (GenBank accession no. KF267450) was analyzed, 
and restriction endonuclease sites required for insertion into the ORFV genome (ORFV121 
locus 55) were removed through silent nucleotide substitutions. In addition, early poxviral 
transcription termination signals (TTTTTNT) present within the coding sequence of PEDV 
S were removed by introducing silent nucleotide mutations. Coding sequences of the His-
tag epitope (6xHis) were added to the 5’ and 3’ends of the S coding sequence. The sequence 
of the VV.7.5 early/late poxviral promoter 132 was added to the 5’end of the PEDV S coding 
sequence. Additionally, HindIII and SalI restriction sites were added to the 5’ and 3’ ends 
of the VV7.5-PEDV-S construct, respectively. A single DNA fragment containing the full 
length PEDV S coding sequences under the control of the VV.7.5 early/late poxviral 
promoter was chemically synthesized (GenScript®, Piscataway, NJ) and subcloned into 
the poxviral transfer vector pZippy-EGFP 133 using HindIII and SalI restriction enzymes 
(pZGFP-PEDV-S). 
 To insert the PEDV-S coding sequences into the ORFV121 genome locus 55, a 
recombination cassette was constructed. ORFV121 left (LF, 1016 bp) and right (RF, 853 
bp) flanking regions were PCR amplified from the ORFV strain IA82 genome with primers 
121LF-Fw(SpeI)-5’-ATTCTTATGCGGCCGCGCAGCACTGCTCGGAGGAGTGCTC-
3’; 121LF-Rv (HindIII)-5’-CAGAATTCGCAAGCTTGGTTGTGTGGGCCAC AGAG 
TTGAG-3’; 121RF-Fw (NotI)-5’-ATTCTTATGCGGCCGCGGAGCACTGCTCGGA 
GGAGTGCT-3’; and 121RF-Rv (BglII)-5’-CAGAATTCGCAGATCTATCATGCGC AG 
CGACGACATCATC-3’and cloned into the vector pZGFP-PEDV-S resulting in the 
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recombination vector pZGFP-121PEDV-S. Correct cloning of ORFV121 LF and RF and 
of PEDV-S were confirmed by restriction enzyme analysis.  
Generation and characterization of the ORFV-PEDV-S recombinant virus. The full 
length PEDV Spike coding sequences were inserted into the ORFV121 locus 55 of the 
ORFV genome  by homologous recombination between the parental ORFV strain IA82 
and the recombination cassette pZGFP-121PEDV-S. OFTu cells cultured in 6-well plates 
were infected with OV-IA82 (multiplicity of infection [MOI] = 1) and 3 h later transfected 
with 2 µg of pZGFP-121PEDV-S DNA using Lipofectamine 3000 (Life Technologies) 
according to the manufacturer’s instructions. At 72 h post-infection/transfection cell 
cultures were harvested, subjected to three freeze-and-thaw cycles and cell lysates used for 
recombinant virus selection by limiting dilution followed by plaque assay. Briefly, OFTu 
cells cultured in 96-well plates were infected with 10-fold serial dilutions of the cell lysates 
(10-1 to 10-3), incubated at 37oC for 72 h, and screened under a fluorescence microscope. 
Wells containing viral foci expressing the green fluorescent protein (GFP) were harvested 
and subjected to one additional round of limiting dilution. GFP positive wells from the 
second limiting dilution were subjected to plaque purification. OFTu cells cultured in 6-
well plates were infected with 10-fold serial dilutions (10-1 to 10-3) of cell lysates from GFP 
positive wells (obtained during the limiting dilutions selection) and overlaid with culture 
medium containing 0.5% agarose (SeaKem GTC agarose, Lonza Inc., Αretta, GA). 
Fluorescent plaques were subjected to five additional rounds of plaque purification. The 
presence of PEDV-S and absence of ORFV121 sequences in the purified recombinant virus 
were confirmed by PCR screening. Primers used for PCR amplification of PEDV-S 
sequences were PEDV-intS-Fw-5’-CGTGGTGGGTTTGGTTGATT-3’ and PEDV-intS-
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Rv-5’-CTGCACGTGGACCTTTTCAA-3’; and 121int-Fw-5’-GGCGGACTAC 
CAGAGACATC-3’ and 121int-Rv-5’-GTCTTCCGGGATGTCGTAGA-3’, respectively. 
PCR amplicons were analyzed by electrophoresis in 1% agarose gels. Insertion and 
integrity of the PEDV full-length spike sequences were confirmed by whole genome 
sequencing using the Nextera XT DNA library preparation kit (Illumina, San Diego, CA) 
followed by sequencing on the Illumina Mi-Seq sequencing platform (Illumina, San Diego, 
CA).  
Immunofluorescence. Expression of PEDV S by the ORFV-PEDV-S recombinant virus 
was assessed by immunofluorescence assay. OFTu cells were infected with the ORFV-
PEDV-S recombinant virus (MOI = 1) and fixed with 3.7% formaldehyde at 24 h post-
infection. After fixation cells were washed three times with phosphate buffer saline (PBS) 
and permeabilized with 0.2% PBS-Triton X100 for 10 min at room temperature (RT). 
Unpermeabilized cells were kept as controls to assess expression of PEDV S on the 
membrane of ORFV-PEDV-S infected cells. Cells were washed three times with PBS and 
incubated with a PEDV S specific mouse monoclonal antibody (SD37-11) for 1 h at room 
temperature (RT). After primary antibody incubation, cells were washed as above and 
incubated with goat anti-mouse IgG (H+L) secondary antibody (Alexa Fluor® 594 
conjugate; Life Technologies, Carlsbad, CA) for 1 h at RT. Cells were washed three times 
with PBS and visualized under a fluorescence microscope.  
Western blot. Expression of PEDV S by the ORFV-PEDV-S recombinant virus was 
assessed by Western blot. OFTu cells cultured in 6-well plates were infected ORFV-
PEDV-S recombinant virus (MOI = 10) and harvested at 48 h post-infection. Cells infected 
with parental ORFV strain IA82 were used as controls. Cells were lysed with M-PER 
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mammalian extraction reagent (Thermo Scientific, Waltham, MA) containing protease 
inhibitors (RPI, Mount Prospect, IL). Fifty micrograms of whole cell protein extracts were 
resolved by SDS-PAGE in 7% acrylamide gels and transferred to nitrocellulose 
membranes. Blots were incubated with 5% non-fat dry milk TBS-Tween 20 (0.1%; TBS-
T) solution for 1 h at RT and probed with 6x-His epitope tag antibody (His.H8, Thermo 
Scientific, Waltham, MA) overnight at 4oC. Blots were washed three times with TBS-T for 
10 min at RT and incubated with a goat anti-mouse IgG-HRP conjugate secondary antibody 
for 2 h at RT. Blots were washed three times with TBS-T for 10 min and developed by 
using a chemiluminescent substrate (Clarity, ECL; Bio-Rad, Hercules, CA). 
Growth curves. Replication properties of ORFV-PEDV-S recombinant virus were assessed 
in vitro. OFTu and PK15 cells were cultured in 6-well plates, inoculated with ORFV-
PEDV-S (MOI = 0.1 [multi-step growth curve] and MOI = 10 [single-step growth curve]) 
and harvested at various time points post-infection (6, 12, 24, 48, and 72 h p.i.). Virus titers 
were determined on each time point using the Spearman and Karber’s method and 
expressed as tissue culture infectious dose 50 (TCID50)/mL.  
Antigens for ELISAs. A truncated form of PEDV S1 protein was expressed as a 
recombinant protein in E. coli, and used in indirect ELISAs to assess antibody responses 
in animals immunized with the ORFV-PEDV-S virus. A fragment of the PEDV S1 protein 
corresponding to nucleotides 1891 to 2400 was amplified from the genome of PEDV strain 
CO13 using standard reverse transcriptase and PCR amplification methods. Primers used 
for PCR amplification were PED-SPikS1-1891(BamHI)-F-5’-CGCGGATCCAC GC 
CTAAACCATTTGAAG-3’ and PED-SpikS1-2400(XhoI)R-5’-CACACTCGAGGTAA 
AGCTGTAAATATTCTGTCC-3’. The PCR amplicon was cloned into the pET-28a 
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eukaryotic expression plasmid (EMD Millipore – Novagen, Billerica, MA) using the 
restriction enzymes indicated on each primer sequence (underlined). The recombinant S1 
protein was expressed in E. coli as a 6X histidine-tagged fusion protein 134 and purified 
using nickel-charged agarose resin (Qiagen, Valencia, CA) according to the manufacture r’s 
recommendations. Affinity purified recombinant protein was refolded and used as antigen 
on indirect ELISAs. DNA sequencing was used to confirm the identity and in frame cloning 
of PEDV S1 with 6X His-tag. 
Animal immunization-challenge studies. The immunogenicity and protective efficacy of 
the ORFV-PEDV-S recombinant virus were assessed in pigs. The efficacy of the vector 
was evaluated by two immunization routes: transcutaneous (TC) and intramuscular (IM). 
The TC route was explored here because it has been shown to induce mucosal and systemic 
immunity in mice and humans (40), and because of the natural tropism of ORFV for skin 
keratinocytes 5. Sixteen 3-week-old pigs, seronegative for PEDV, were randomly allocated 
to four experimental groups as follows: Group 1, sham-immunized/mock-challenged (n = 
4); Group 2, ORFV-PEDV-S-immunized/PEDV challenged (n = 4); Group 3, ORFV-
PEDV-S-immunized/PEDV challenged (n = 4); and Group 4, sham-immunized/P EDV 
challenged (n = 4) (Table 1). Animals from groups 1 and 4 were immunized with a control 
ORFV vector expressing GFP (ORFV-GFP) and received the vaccine via TC (1 mL) and 
IM routes (1 mL). Animals from group 2 were immunized with the ORFV-PEDV-S 
recombinant virus via the TC route, while animals in group 3 were immunized by the IM 
route. Intramuscular immunization was performed by injection of 2 mL of a virus 
suspension containing 107.38 TCID50/mL in MEM into the neck. For the TC immuniza t ion 
the skin of the inguinal region was scarified with a sterile scalpel blade and the virus 
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suspension containing 107.38 TCID50/mL in MEM was applied topically to the scarified 
skin area using a sterile cotton swab (~4 cm2). All animals were immunized on day 0 and 
received two booster immunizations on days 21 and 45 post-primary immunization.  Serum 
samples were collected on days 0, 7, 14, 21, 35, 42, 49, 53, 56 and 60 post-immunization. 
The protective efficacy of recombinant ORFV-PEDV-S virus was assessed 
following challenge infection with PEDV. On day 60 post-immunization, animals from 
Group 1 received 2 mL of MEM orally (mock-challenge), while animals from groups 2, 3 
and 4 were challenged orally with a virus suspension containing 2 x 105 TCID50 of PEDV 
strain CO13. Animals were monitored daily for clinical signs of PED. Clinical signs were 
recorded and individual daily scores assigned to all animals based on the following criteria: 
0 = normal feces, 1 = pasty feces, 2 = moderate diarrhea (semi-liquid), 3 = diarrhea (liquid), 
4 = severe diarrhea (very liquid), 5 = watery diarrhea (profuse diarrhea) 137. Mean daily 
group scores were calculated and compared among different treatment groups. Fecal swabs 
were collected on day 0, 3, 5, 7, 9, 11 and 14 post-challenge to assess virus shedding in 
feces. Serum samples were collected on days 0, 3, 7, 10 and 14 post-challenge to evaluate 
humoral and cell mediated responses. All animals were euthanized on day 14 post-
challenge. Animal immunization-challenge studies were conducted at SDSU Animal 
Resource Wing (ARW), following the guidelines and protocols approved by the SDSU 
Institutional Animal Care and Use Committee (IACUC approval no. 15-063A). 
Antibody isotype ELISAs. PEDV specific IgG and IgA antibody responses elicited by 
immunization with the recombinant ORFV-PEDV-S virus were assessed by S1 indirect 
ELISAs, while responses post-challenge infection were assessed by the S1 and 
nucleoprotein (N) 134 ELISAs. Optimal assay conditions (amount of antigen, serum and 
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secondary antibody dilutions) were determined by a checkerboard titration. Polystyrene 
microtiter plates (Immunolon 1B, Thermo Scientific, Waltham, MA) were coated with the 
appropriate antigen (S1, 100 ng/well; and N, 25 ng/well 134) in bicarbonate/carbonate 
coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6) in alternate 
wells. After incubation at 37oC for 1 h, plates were washed four times with PBS tween 20 
(PBS-T, 0.05%) and blocked overnight at 4oC with PBS-T 5% non-fat dry milk. Blocking 
reagent was removed and plates washed three times with PBS-T (300 µl). Test and control 
serum samples were diluted (1:50) in PBS-T 5% non-fat dry milk, and 100 µl of diluted 
samples were added to paired coated and uncoated control wells and incubated at room 
temperature for 1 h. Unbound antibodies were washed with PBS-T (three times) and plates 
incubated with biotinylated secondary antibodies against swine IgG or IgA (Bethyl 
Laboratories, TX) followed by incubation with streptavidin-HRP conjugate (Pierce, 
Rockford, IL). Reactions were developed with 3,3’,5’5’ – tetramethylbenzidine substrate 
(TMB) (KPL Inc., Gaithersburg, MA) and OD values determined at 450 nm using a 
microplate reader (BioTek Instruments Inc., Winooski, VT). OD values for each test and 
control samples were normalized to the OD value of uncoated wells and results expressed 
as sample to positive (S/P) ratios that were calculated as follows: S/P = optical density 
(OD) of sample – OD of buffer/OD of positive control – OD of buffer. All assay formats 
were pre-validated at the SD ADRDL using serum samples from animals of known 
serological status.  
Fluorescent focus neutralization assay. Neutralizing antibody responses elicited by 
immunization with the recombinant ORFV-PEDV-S were assessed by fluorescent focus 
neutralization assay (FFN) as previously described 134. Endpoint neutralizing antibody 
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titers were determined as the highest dilution of serum capable of reducing 90% of PEDV 
fluorescent foci relative to negative control samples. A FFN titer <20 was considered 
negative. 
Viral RNA extraction and real-time RT-PCR. Viral nucleic acid was extracted from fecal 
swabs using the MagMAX viral RNA/DNA isolation kit (Life Technologies, Carlsbad, 
CA) following the manufacturer’s instructions. Shedding of PEDV in feces was assessed 
using a commercial multiplex real-time RT-PCR (rRT-PCR) kit targeting the spike gene 
of PEDV, and other enteric coronaviruses including transmissible gastroenteritis virus 
(TGEV) and porcine deltacoronavirus (PDCoV) (EZ-PED/TGE/PDCoV MPX 1.0, 
Tetracore Inc., Rockville, MD). Genome copy number per mL were determined using the 
relative standard curve method. All calculations were performed using a 4-parameter 
logistic regression curve. rRT-PCR tests were performed at the SDSU Animal Disease and 
Research Diagnostic Laboratory (ADRDL).    
Statistical analysis. Statistical analysis was performed using SPSS 14 software. One-way 
analysis of variance with Tukey HSD multiple comparison test was performed on all 
groups, using harmonic mean sample size of 4 to account for equal group sizes. 
Nonparametric Krustal-Wallis test was used to assess differences in virus shedding 
between treatment groups. Differences between groups were considered significant at 
P<0.05.  
Results 
Generation and characterization of the ORFV-PEDV-S recombinant virus. The full-
length spike protein of PEDV was inserted into the ORFV121 55 genome locus of ORFV 
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by homologous recombination. ORFV121 55, was deleted from the ORFV genome and 
replaced by a DNA fragment encoding full-length PEDV S protein and the reporter gene 
encoding the green fluorescent protein (GFP) under the control of individual early/late 
VV7.5 poxviral promoters (Fig. 1A). The recombinant virus was selected and purified by 
limiting dilution followed by plaque assays based on expression of the green fluorescence 
protein (GFP) (Fig. 1C). Deleted ORFV121 gene sequences were not detected in the 
purified recombinant virus (Fig. 1B).  In contrast, PEDV S sequences were detected in the 
recombinant virus but not in the wild type ORFV genome (Fig. 1B). Complete genome 
sequence of the ORFV-PEDV-S recombinant virus confirmed the insertion of the full-
length coding sequences of PEDV S (data not shown). 
Replication properties of the ORFV-PEDV-S recombinant virus were assessed in 
vitro. No differences in replication kinetics and viral yields were observed when multip le -
step or one-step growth curves of ORFV-PEDV-S were compared to those of the wild-type 
OV-IA82 virus in primary ovine fetal turbinate (OFTu) cell cultures (data not shown). 
Replication kinetics of ORFV-PEDV-S was also assessed in porcine kidney cells (PK-15). 
Notably, replication of ORFV-PEDV-S in PK-15 cells was markedly impaired when 
compared to its replication in natural host OFTu cells (Fig. 3A and 3B). Similar replication 
kinetics was observed in swine testicle cells (ST, data not shown). These results indicate a 
marked growth defect for ORFV-PEDV-S in swine cells, demonstrating only minimal 
virus replication in cells of swine origin.  
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The recombinant ORFV-PEDV-S expresses PEDV S in vitro. Expression of PEDV S by 
ORFV-PEDV-S recombinant virus was assessed by immunofluorescence and Western blot 
assays. Expression of PEDV S by the recombinant ORFV-PEDV-S was assessed during 
virus infection in OFTu cells by using an S-specific monoclonal antibody in an indirect 
IFA assay. High levels of PEDV S were detected in ORFV-PEDV-S infected cells (Fig. 
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1C). Similarly, high levels of the full length PEDV S (~150 kDa) were detected in ORFV-
PEDV-S infected cells by Western blot assays (Fig. 1D). 
 Intracellular or surface expression of PEDV S by the recombinant ORFV-PEDV-S 
was assessed by IFA assays. As shown in Fig. 2A, PEDV S expression was detected in 
permeabilized (Triton X-100) and in unpermeabilized cells, indicating abundant 
localization of PEDV S on the surface and intracellular compartment of ORFV-PEDV-S 
infected cells.  
 The stability of PEDV S gene inserted into the ORFV121 locus of the ORFV-
PEDV- The stability of PEDV S gene inserted into the ORFV121 locus of the ORFV-
PEDV-S genome was assessed by IFA assays and confirmed by PCR and DNA sequencing 
following serial passages of the recombinant virus in vitro. Expression of PEDV S was 
consistently detected on ORFV-PEDV-S infected cells after 1, 5 or 10 passages of the 
recombinant virus in cell culture in vitro (Fig. 3b). Additionally, the full length PEDV S 
was amplified from the recombinant virus on passages 1, 5 and 10 and sequencing of the 
p.10 full length S revealed 100% identity with the S sequences inserted in the recombinant 
virus (data not shown). Together, these results demonstrate the stability of PEDV S inserted 
into the ORFV121 locus.   
Intramuscular (IM) immunization with ORFV-PEDV-S induces serum IgG and IgA 
antibody responses against PEDV in pigs. The immunogenicity of ORFV-PEDV-S 
recombinant virus was evaluated in pigs following transcutaneous (TC) or intramuscular 
(IM) immunizations. Animals were immunized with ORFV-PEDV-S via the TC or IM 
routes on day 0, and received booster immunizations on days 21 and 45 post-primary 
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immunization (Table 1). Serological responses elicited against PEDV were monitored by 
indirect S1 IgG- and IgA-isotype ELISAs. All animals immunized via the IM route with 
the recombinant ORFV-PEDV-S virus developed IgG and IgA antibody responses against 
PEDV S (Group 3; Fig. 4A and 4B), whereas no antibody responses were detected in the 
animals immunized via the TC route (Group 2) or in animals from control groups (Group 
1 and Group 4), immunized with ORFV-GFP vectors (Group 1 and 4; Fig. 4A and 4B). 
Antibodies were first detected on animals from Group 3 (IM) on day 28 post-immuniza t ion 
(p.i.), following the booster immunization on day 21 (Fig. 4A and 4B). Notably, while a 
second booster immunization elicited anamnestic antibody responses in animals 
immunized by the IM route, no serological responses were detected in animals immunized 
by the TC route (Fig. 4A and 4B). Similar results were observed when serologica l 
responses were monitored using a whole virus (PEDV) indirect ELISA (data not shown). 
These results demonstrate that IM immunization with ORFV-PEDV-S elicits robust 
antibody (IgG and IgA) responses in immunized pigs.     
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IM immunization with ORFV-PEDV-S induces neutralizing antibody responses against 
PEDV in pigs. The ability of ORFV-PEDV-S to induce neutralizing antibody (NA) 
responses against PEDV was assessed using an FFN assay 134. Similar to the serologica l 
responses detected with the IgG and IgA isotype ELISAs, virus neutralization assays 
revealed that IM immunization with ORFV-PEDV-S elicited NA responses against PEDV 
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in all immunized animals (Fig. 4C). No NA responses were detected in animals immunized 




Table 1. Experimental design of animal immunization-challenge infection. 
Groupa Vector construct Route Immunization 
days 
Challenge infectiond 
Inoculum Day p.i. 
1 ORFV-GFP TCb + IMc 0, 21, 45 MEM 60 
2 ORFV-PEDV-S TC 0, 21, 45 PEDV CO13  60 
3 ORFV-PEDV-S IM 0, 21, 45 PEDV CO13  60 
4 ORFV-GFP TC + IM 0, 21, 45 PEDV CO13  60 
aEach group consisted of four three-week-old weaned piglets. 
bTC: transcutaneous. Virus suspension was instilled on a 4 cm2 area of scarified skin. 
cIM: intramuscular. Virus suspension was injected intramuscularly. 
dEach animal was challenged orally with a virus suspension containing 2 x 105 TCID50 of PEDV strain 
CO13. 
 
IM immunization with ORFV-PEDV-S protects pigs from clinical PED. To evaluate the 
protective efficacy of the recombinant ORFV-PEDV-S, pigs from Groups 2, 3 and 4 (Table 
1) were challenged orally with the virulent PEDV strain CO13 on day 60 p.i. (2 x 105 
TCID50/animal). Clinical signs of PED and virus shedding in feces were monitored after 
challenge infection. Notably, characteristic clinical signs of PEDV infection were observed 
in 2/4 (50%) animals from the sham-immunized group (Group 4), and in ¾ (75%) animals 
from the TC immunized group (Group 2), while no animals immunized via the IM route 
(0/4) (Group 3) developed clinical signs of PED. Daily average clinical scores were 
recorded for each group, and are presented in Fig. 5A. Control sham-immunized animals 
(Group 4) and TC immunized animals (Group 2) presented significantly higher clinica l 
scores when compared to sham-immunized non-challenged animals (Group 1) or to ORFV-
PEDV-S immunized (IM) PEDV challenged animals (Group 3) (Fig. 5).  
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 Virus shedding in feces was evaluated after challenge infection using rRT-PCR. 
Rectal swabs collected from all animals on days 0, 3, 5, 7, 9, 11 and 14 post-challenge 
(p.c.) infection were tested by PEDV rRT-PCR and the duration of virus shedding as well 
as PEDV genome copy numbers were compared between treatment groups. All challenged 
animals (Groups 2, 3 and 4) shed PEDV in feces, while no virus shedding was detected in 
non-challenged animals (Group 1) throughout the experiment (Table 2). Notably, both 
duration and magnitude of PEDV shedding were markedly decreased in animals from 
Group 3, immunized via the IM route with the ORFV-PEDV-S virus (Table 2; Fig. 5B). 
While ¾ animals in Group 2 (75%) and 4/4 animals in Group 4 (4/4; 100%) were positive 
on day 3 p.c., only ¼ animal in Group 3 (25%) was positive for PEDV (Table 2). Animals 
in Group 3 shed PEDV in feces between days 7 and 9 p.c.; however, they ceased shedding 
virus earlier than animals from Groups 2 and 4 (Table 2). While on day 11 p.c. only ¼ 
(25%) animal from Group 3 was positive, all 4/4 (100%) animals in Groups 2 and 4 were 
still shedding PEDV. Quantitation of PEDV genome copy numbers in fecal swabs revealed 
a lower amount of the virus being shed in feces by animals from Group 3, compared to 
animals from Groups 2 and 4 (Fig. 5B). Together these results indicate that immune 
responses elicited by IM immunization with the recombinant ORFV-PEDV-S led to 




The serological responses post-challenge with PEDV were evaluated by S1 IgG 
and IgA ELISAs, virus neutralization assays and N IgG ELISA. Only animals in Group 3 
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presented detectable anti-S and PEDV NA antibodies in serum (Fig. 5A, 5B and 5C and 
6A, 6B and 6C) at the day of challenge (day 60 p.i.). Serological responses of each group 
were markedly different following challenge infection. Animals from Group 2 (which did 
not seroconvert after TC immunization) and from Group 4 (control sham-immunized 
group) developed lower levels of S-specific IgG and IgA and neutralizing antibodies (days 
10 and 14 p.c.) when compared to animals in Group 3 (which seroconverted after IM 
immunization with ORFV-PEDV-S) (Fig. 6A, 6B and 6C). Notably, levels of NA 
antibodies detected in animals from Group 3 were 3-4 fold higher than those in animals in 
Groups 2 and 4 (Fig. 6C). In contrast, serum IgG responses against PEDV N were more 
robust in animals from Groups 2 and 4 when compared to animals from Group 3 (Fig. 6D). 
These differences were more pronounced at early times p.c. (day 7 p.c.; P<0.05), with 
comparable levels of anti-N antibodies being detected at later times post challenge (Fig. 
6D). These results indicate an efficient priming of B-lymphocytes by IM immuniza t ion 
with the recombinant ORFV-PEDV-S, and further demonstrate a robust and typical 










Table 2. Virus shedding in feces after challenge infection with PEDV. 
Group Animal ID Virus shedding (day post-challenge)a 
  0 3 5 7 9 11 14b 
1 1 - - - - - - - 
 2 - - - - - - - 
 3 - - - - - - - 
 4 - - - - - - - 
2 5 - + + + + + + 
 6 - + + + + + - 
 7 - - + + + + - 
 8 - + + + + + - 
3 9 - + + + + + - 
 10 - - - + + - - 
 11 - - - + + - - 
 12 - - + + + - - 
4 13 - + + + + + - 
 14 - + + + + + - 
 15 - + + + + + + 
 16 - + + + + + - 
aVirus shedding was assessed by real-time PCR in fecal swabs. 





The immunogenicity and protective efficacy of ORFV-based vectored vaccine 
candidates have been demonstrated in multiple animal species 72–77. Notably, ORFV 
recombinants, based on the highly attenuated ORFV strain D1701, expressing the PRV gC- 
and gD- or the CSFV E2 glycoproteins have been shown to protect pigs against challenge 
with PRV and CSFV, respectively 72,76,77,122. Here we explored the potential of ORFV as a 
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vaccine delivery vector for enteric pathogens of swine. Using a well characterized ORFV 
strain (OV-IA82) 2,54–56 and the locus of a recently identified virulence determinant of 
ORFV (ORFV121) as insertion site, we generated a recombinant ORFV expressing the 
full- length PEDV S protein.  
The S is the major envelope glycoprotein of PEDV and has been shown to be the 
main target of neutralizing antibodies 126–128. Additionally, subunit PEDV vaccine 
candidates based on the S protein have been shown to induce protective immune responses 
in pigs 90. Here, the coding sequences of the full length PEDV S were inserted into the 
ORFV121 gene locus 55 of the ORFV genome. The recombinant ORFV-PEDV-S was 
successfully generated (Fig. 1B, 1C and 1D), and sequencing of the virus confirmed the 
insertion of PEDV S- and deletion of the ORFV121 gene from the ORFV genome. These 
results demonstrate the feasibility of ORFV121 gene locus as an insertion site for 
heterologous antigens in ORFV-based recombinant vectors. Notably, the DNA fragment 
inserted into the ORFV121 locus is ~5.2 kbp in length (full- length S- and GFP coding 
sequences, and promoter sequences), demonstrate that the ORFV121 locus may 
accommodate large fragments of heterologous DNA. Successful expression of both PEDV 
S and the GFP proteins in cells infected with the recombinant ORFV-PEDV-S (Fig. 1C 
and 2A), confirmed the large payload capacity of the ORFV121 gene locus and of ORFV-
based vectors.     
The expression and genetic stability of PEDV S carried by the recombinant ORFV-
PEDV-S virus were assessed in infected cell cultures. Immunofluorescence assays 
performed in cell cultures infected with the recombinant ORFV-PEDV-S and 
permeabilized or not with Triton X-100 revealed high levels of PEDV S expression 
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intracellularly and on the cell surface (Fig. 2A). While intracellular expression of PEDV S 
may allow for antigen processing and presentation through the MHC I pathway, expression 
of the protein on the surface of infected cells may allow for direct recognition and uptake 
of the protein by antigen presenting cells (APCs) or by B lymphocytes, thus potentially 
leading to stimulation of both cellular and humoral immune responses 138. An important 
requirement for viral vectors is the stability of heterologous genes within their genome 139. 
As shown in Fig. 2B, serial passage of ORFV-PEDV-S in cell cultures in vitro did not 
affect expression of PEDV S. High levels of the PEDV S protein were detected in cell 
cultures infected with passages 1, 5 and 10 of the recombinant ORFV-PEDV-S, 
demonstrating the genetic stability of the insert into the ORFV121 gene locus.   
The immunogenicity of the recombinant ORFV-PEDV-S was evaluated in pigs 
following IM or TC immunizations. While IM immunization has been shown effective for 
other ORFV vectored antigens in pigs 76,77, proof-of-concept TC immunization was used 
given its efficacy in inducing mucosal immune responses in other animal species 135.  
Notably, animals immunized via the IM route developed robust antibody responses (IgG, 
IgA and NA) against PEDV, whereas no seroconversion was detected in animals 
immunized via the TC route (Fig. 4A, 4B and 4C). These results corroborate the findings 
of previous studies 76,77, demonstrating that the IM route is an effective route to deliver 
ORFV-vectored antigens in swine. Although no neutralizing antibodies against ORFV 
were detected in any of the immunized animals (data not shown), it is possible that local 
innate/inflammatory responses elicited by skin scarification may have affected the delivery 
and/or expression of PEDV S by ORFV-PEDV-S in the skin, thus, precluding the 
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development of immune responses against PEDV S in animals immunized via the TC 
route.  
The protective efficacy of the recombinant ORFV-PEDV-S virus was assessed in 
swine. Animals from Groups 2 (TC) and 3 (IM), and sham-immunized Group 4 (TC + IM), 
were challenged orally with a virulent PEDV strain CO13 (2 x 105 TCID50). Notably, while 
3 out of 4 (3/4; 75%) animals from Group 2 (which did not seroconvert after TC 
immunization; Fig. 4A, 4B and 4C) and 2/4 (50%) animals from control Group 4 developed 
characteristic signs of PED, none of the animals from Group 3 (IM, which developed serum 
antibody responses to PEDV) were affected. Additionally, animals from Group 3 presented 
reduced virus shedding in feces when compared to animals from Groups 2 and 4 (Fig. 5A 
and 5B; Table 2). Results from rRT-PCR performed in rectal swabs show a delayed onset 
and short duration shedding of PEDV by animals from Group 3 (Fig. 5B; Table 2). 
Together, these results demonstrate that IM immunization with the recombinant ORFV-
PEDV-S protected pigs from clinical PED and reduced virus shedding following oral 
challenge- infection. Although results here show a strong correlation between PEDV-
specific antibodies in serum, protection from clinical disease and decreased virus shedding 
in feces, the precise immunological mechanisms underlying these findings were not 
defined in our study. In future studies, it would be interesting to assess, for example, 
whether IM immunization with the recombinant ORFV-PEDV-S elicits secretory IgA 
(sIgA) responses at mucosal surfaces, or perhaps, homing of effector B or T lymphocytes 
to the intestinal mucosa. 
Serological responses that followed challenge infection with PEDV varied 
significantly between immunized groups. While animals from Group 3 presented a robust 
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serological response, typical of a secondary immunological response, characterized by high 
levels of S-specific and neutralizing antibody responses to PEDV (Fig. 6A, 6B and 6C), 
animals from Groups 2 and 4 developed delayed antibody responses, typical of primary 
exposure to PEDV and characterized by lower levels of S-specific and NA antibodies (Fig. 
6A, 6B and 6C). In contrast, antibody responses to N were lower in animals from Group 3 
(day 7 p.c.), suggesting an early inhibition of PEDV infection/replication (Fig. 6D). Taken 
together, these results indicate that IM immunization with the recombinant ORFV-PEDV-
S virus efficiently primed B cells, which rapidly and effectively responded upon exposure 
to the virus in the intestinal mucosa, leading to anamnestic antibody responses in 
immunized animals.  
Although correlate(s) of protection for PEDV remain unknown, neutralizing 
secretory IgA (sIgA) antibodies are thought to play a major role in protection 136,140–142. 
sIgA seem especially important in providing lactogenic immunity and protection during 
the first days of life of newborn piglets 141,143. One of the main obstacles in elicit ing 
lactogenic immunity to PEDV, however, is the need for local gut stimulation of IgA 
secreting cells (plasmablasts) and their subsequent migration to the mammary gland where 
they produce sIgA antibodies which are secreted in the colostrum and milk and ultima te ly 
transferred to suckling piglets (gut-mammary-sIgA axis) 110. This has only been achieved 
by natural infection or by oral vaccination of pregnant sows with live PEDV vaccines 
106,137,144. Results here show protection of nursery pigs to oral PEDV challenge after IM 
immunization with the recombinant ORFV-PEDV-S. Whether this vector construct is 
capable of eliciting lactogenic immunity and protection in neonatal piglets remains to be 
determined. Nevertheless, the fact that IM immunization with the recombinant ORFV-
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PEDV-S led to protective immune responses in naïve animals indicates that this virus 
vector could be a useful tool for the control of PEDV in endemic areas. The recombinant 
ORFV-PEDV-S could be used to immunize naïve gilts prior to their introduction to PEDV 
positive farms or to boost the immunity of pregnant gilts/sows that have been naturally 
exposed to the virus.  
In summary, here we show the successful generation of a recombinant ORFV 
containing the full-length S gene of PEDV into the ORFV121 gene locus. Characterizat ion 
of the recombinant ORFV-PEDV-S virus in vitro demonstrates efficient and stable 
expression of the heterologous protein in cell cultures infected with the recombinant virus. 
Immunization-challenge studies in pigs, show that IM delivery of the recombinant ORFV-
PEDV-S elicits robust serum antibody responses in immunized animals that correlated with 
protection against clinical PED and decreased virus shedding in feces. These results 
demonstrate the potential of ORFV vectored vaccines for prevention of enteric infect ions 
in swine.   
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Chapter 3: Conclusion 
Conclusion 
ORFV-vectored vaccines have become increasingly popular as an alternative to 
traditional poxvirus-vectors because of their safety and ability to induce robust, dual-armed 
immune responses 72,74,120,145,73,75,18,71. Most ORFV-vectored vaccines utilize a cell-culture 
attenuated D1701 strain and have been used to deliver antigens from a diverse range of 
diseases, including the H5 protein of influenza, and the glycoproteins of rabies, 
pseudorabies, and classical swine fever virus 73,75–77. The VEGF locus has been the site of 
choice for DNA insertion because of its importance for ORFV virulence and pathogenesis 
72,74,120,75,77.  
In our study we explored the feasibility of ORFV121, an ORFV virulence 
determinant which encodes for an NF-κB inhibitor 55, as an insertion site for heterologous 
genes in ORFV-based vectors. For this, the full length S protein of PEDV was used as a 
model antigen and a recombinant ORFV-PEDV-S was generated. Successful insertion of 
PEDV-S into the ORFV121 locus was confirmed by PCR (Fig. 1B), and in vitro expression 
was confirmed by IFA and Western blot (Fig. 1C and 1D). 
One of the benefits of ORFV is a restricted host range that is typically limited to 
sheep and goats 72,18. Additonally, D1701 ORFV-vectors have been proven safe and highly 
attenuated, almost to the point of being apathogenic 15,146. Similarly, immunization of pigs 
with ORFV-PEDV-S did not result in any adverse reaction even after repeated 
immunization boosts. Previous studies have shown that deletion of ORFV121 significantly 
reduces the severity and duration of disease in the natural host of the virus55.   Experimenta l 
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infection of swine cells in vitro failed to result in productive virus replication (Fig. 3A and 
3B). 
 The ORFV-PEDV-S construct efficiently expressed PEDV-S in vitro and in vivo, 
as evidenced by detection of the protein in infected cell cultures or detection of PEDV-S-
specific antibodies in immunized animals. Animals that received IM immunizations with 
the ORFV-PEDV-S construct (Group 3) presented high levels of IgG, IgA, and neutralizing 
antibodies against PEDV (Fig. 4A, 4B, and 4C), indicating successful protein expression 
and delivery by ORFV-PEDV-S in vivo. This memory translated into complete protection 
of Group 3 animals from clinical PED (Fig. 5A) and reduced the magnitude and duration 
of virus shedding upon live virus challenge (Table 2). This protection correlated with 
significantly higher levels of IgG, IgA, and neutralizing antibodies in the serum of Group 
3 animals when compared to those receiving TC (Group 2) or sham (Group 4) 
immunizations.    
 In conclusion, we provide further evidence of an ORFV-vectored vaccine being 
used to successfully protect animals against viral disease. Additionally, our study 
demonstrates the feasibility of ORFV121 as an insertion site for heterologous antigens in 
ORFV-based vectors. Although there are many other studies in which ORFV has been used 
to vaccinate animals experimentally, further research will be necessary to optimize ORFV-
vectors to improve vaccine efficacy and promote enduring immunological memory. 
Determining alternate insertion sites, optimizing the immunogenicity of inserted antigens, 
and enhancing expression of foreign DNA may all contribute to improving the efficacy of 
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